MTOR and head and neck squamous cell carcinoma: Buparlisib is an oral pan-PI3K inhibitor and in HNSCC xenograft models, led to down-regulation of PI3K–mTOR pathway signaling, with reduced tumor hypoxia and vascular remodeling (91).